Nonalcoholic steatohepatitis (NASH) is poised to become the leading cause of liver transplants by 2020.
Our FounderDr. Adnan Mjalli, established our facility in 2008 to conduct early-stage clinical pharmacology and Proof of Concept studies in Patient populations. Our long history of diabetes and obesity research makes us aResearch Destination and a premier research facility ideally suited to qualify, enroll and execute studies involving Patients with NASH.
ENHANCED PATIENT ACCESS
15,000+ Patients with metabolic disease, obesity, and elevated liver enzymes
Proactive pre-screening initiatives collecting relevant Patient data: medical history, blood chemistry, CAP scores with Fibroscan, eGFR values and others
Extensive Clinical Pharmacology and POC study experience
30+ metabolic disorder studies
PK/PD, Efficacy, and Safety
SAD/MAD and POC Adaptive Designs
Wide range of ROA capabilities
In-house Fibroscan Screening & Diagnosis
MRI and Liver Biopsy confirmed patients
Strategic alliances for Metabolomics, Biomarker and Clinical Endpoint Assays
“NAFLD can be a life-threatening condition with no currently approved therapy that is often undiagnosed. Our goal is to bring awareness to both the disease and opportunity for Patients to participate in promising clinical research studies”